MedPath

Comparing ormeloxifene (a contraceptive) and medroxyprogesterone acetate (hormone supplement) in heavy periods patients

Phase 2
Conditions
Health Condition 1: N924- Excessive bleeding in the premenopausal periodHealth Condition 2: N924- Excessive bleeding in the premenopausal period
Registration Number
CTRI/2024/01/061782
Lead Sponsor
Sri manakula vinayagar medical college and hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Reproductive age group women

Exclusion Criteria

No structural abnormality

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of ormeloxifene and medroxyprogesterone acetate in acute heavy menstrual bleedingTimepoint: 4 months
Secondary Outcome Measures
NameTimeMethod
To study the effect of ormeloxifene and medroxyprogesterone acetate on Endometrial thicknessTimepoint: 4 months
© Copyright 2025. All Rights Reserved by MedPath